FDA Clarifies GLP-1 Compounding as Shortages Evolve

Key Takeaways:

• FDA reiterates that 503A compounding must be patient-specific and is restricted when products are “essentially copies” of commercially available drugs.
• The agency describes its interpretation of “essentially a copy,” including an illustrative example involving semaglutide combined with another ingredient.
• Enforcement discretion for GLP-1 compounding is tied to shortage status and is time-limited, with FDA maintaining authority to act on safety, quality, and other violations.

In an FDA April 1, 2026 statement on compounders and GLP-1 supply, the agency reiterated that specific conditions must be met for compounded drugs to qualify for exemptions under FD&C Act sections 503A and 503B. The communication highlights (1) the 503A requirement for patient-specific prescriptions and limits related to products that are “essentially copies” of commercially available drugs, (2) how FDA describes its interpretation of the “essentially a copy” concept, and (3) time-limited enforcement discretion tied to whether semaglutide injection products remain on FDA’s drug shortage list. The statement also reiterates that FDA may take action on other statutory or regulatory issues during these periods.

For 503A, FDA emphasizes that a drug product must be compounded for an identified individual patient based on a valid prescription and reiterates statutory constraints on compounding products that are essentially copies of commercially available drugs, including limits on producing such products “regularly or in inordinate amounts.” The agency also outlines additional 503A conditions. By contrast, 503B outsourcing facilities are described as operating under a different exemption framework, with distinct requirements—including restrictions on compounding from bulk drug substances unless criteria such as inclusion on a bulks list or drug shortage list are met, among other requirements.

FDA describes its interpretation of “essentially a copy” as depending on whether the compounded product has the same active ingredient(s), strength (or similar/easily substitutable strength), and route of administration as a commercially available product. The statement also notes that a prescriber-documented “significant difference” for an individual patient may justify compounding in certain cases. As an illustrative example, FDA notes that a compounded product combining semaglutide with another active ingredient (e.g., vitamin B12) may still be considered essentially a copy if route of administration and strength are similar to an approved product.

On enforcement discretion, FDA provides updated timelines for when prior non-action policies related to semaglutide and tirzepatide compounding have ended or are scheduled to end for 503A pharmacies and, separately, for 503B outsourcing facilities. These timelines are linked to FDA’s drug shortage determinations and referenced court actions affecting timing. The agency emphasizes that enforcement discretion is time-limited and does not constitute approval or exemption from all regulatory requirements, and that FDA may still take action in cases involving safety, quality, or other statutory concerns.